Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-28T02:49:47.677Z Has data issue: false hasContentIssue false
  • English
  • Français

Thyrotoxic periodic paralysis triggered by β2- adrenergic bronchodilators

Published online by Cambridge University Press:  04 March 2015

Fu-Chiang Yeh ,
Wen-Fang Chiang ,
Chih-Chiang Wang  and
Shih-Hua Lin
Fu-Chiang Yeh
Affiliation:
Division of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
Wen-Fang Chiang
Affiliation:
Division of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan Department of Medicine, Armed Forces Taoyuan General Hospital, Taoyuan, Taiwan
Chih-Chiang Wang
Affiliation:
Department of Medicine, Armed Forces Kaohsiung General Hospital, Kaohsiung, Taiwan
Shih-Hua Lin*
Affiliation:
Division of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
*
Division of Nephrology, Department of Medicine, Tri-Service General Hospital, No. 325, Section 2, Cheng-Kung Road, Neihu 114, Taipei, Taiwan, ROC;l521116@gmail.com

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Hypokalemic periodic paralysis is the most common form of periodic paralysis and is characterized by attacks of muscle paralysis associated with a low serum potassium (K+) level due to an acute intracellular shifting. Thyrotoxic periodic paralysis (TPP), characterized by the triad of muscle paralysis, acute hypokalemia, and hyperthyroidism, is one cause of hypokalemic periodic paralysis. The triggering of an attack of undiagnosed TPP by β2-adrenergic bronchodilators has, to our knowledge, not been reported previously. We describe two young men who presented to the emergency department with the sudden onset of muscle paralysis after administration of inhaled β2-adrenergic bronchodilators for asthma. In both cases, the physical examination revealed an enlarged thyroid gland and symmetrical flaccid paralysis with areflexia of lower extremities. Hypokalemia with low urine K+ excretion and normal blood acid-base status was found on laboratory testing, suggestive of an intracellular shift of K+, and the patients' muscle strength recovered at serum K+ concentrations of 3.0 and 3.3 mmol/L. One patient developed hyperkalemia after a total potassium chloride supplementation of 110mmol. Thyroid function testing was diagnostic of primary hyperthyroidism due to Graves disease in both cases. These cases illustrate that β2-adrenergic bronchodilators should be considered a potential precipitant of TPP.

Keywords

β2-adrenergic bronchodilatorhyperthyroidismhypokalemiaparalysisperiodic paralysis
Type
Case Report • Rapport de cas
Information
Canadian Journal of Emergency Medicine , Volume 16 , Issue 3 , May 2014 , pp. 247 - 251
Copyright
Copyright © Canadian Association of Emergency Physicians 2014

References

REFERENCES

1. Raja Rayan, DL, Hanna, MG. Skeletal muscle channelopathies: nondystrophic myotonias and periodic paralysis. Curr Opin Neurol 2010;23:466–76, doi:10.1097/WCO.0b013e32833cc97e.Google Scholar
2. Lin, SH, Davids, MR, Halperin, ML. Hypokalaemia and paralysis. QJM 2003;96:161–9, doi:10.1093/qjmed/hcg021.CrossRefGoogle ScholarPubMed
3. Lin, SH. Thyrotoxic periodic paralysis. Mayo Clin Proc 2005;80:99–105.Google Scholar
4. Maciel, RM, Lindsey, SC, Dias da Silva, MR. Novel etiopathophysiological aspects of thyrotoxic periodic paralysis. Nat Rev Endocrinol 2011;7:657–67, doi:10.1038/nrendo.2011.58.Google Scholar
5. Brown, MJ, Brown, DC, Murphy, MB. Hypokalemia from beta2-receptor stimulation by circulating epinephrine. N Engl J Med 1983;309:1414–9, doi:10.1056/NEJM198312083092303.CrossRefGoogle ScholarPubMed
6. Ryan, DP, da Silva, MR, Soong, TW, et al. Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell 2010;140:88–98, doi:10.1016/j.cell.2009.12.024.Google Scholar
7. Cheng, CJ, Lin, SH, Lo, YF, et al. Identification and functional characterization of Kir2.6 mutations associated with non-familial hypokalemic periodic paralysis. J Biol Chem 2011;286:27425–35, doi:10.1074/jbc.M111.249656.Google Scholar
8. El-Hennawy, AS, Nesa, M, Mahmood, AK. Thyrotoxic hypokalemic periodic paralysis triggered by high carbohydrate diet. Am J Ther 2007;14:499–501, doi:10.1097/MJT.0b013e31814daf53.Google Scholar
9. Akar, S, Comlekci, A, Birlik, M, et al. Thyrotoxic periodic paralysis in a Turkish male; the recurrence of the attack after radioiodine treatment. Endocr J 2005;52:149–51, doi:10.1507/endocrj.52.149.Google Scholar
10. Aldemir, M, Gülogğlu, C, Balakan, O, et al. Thyrotoxic periodic paralysis: a case report and review of the literature. Eur J Gen Med 2004;1:48–51.Google Scholar
11. Moratinos, J, Reverte, M. Effects of catecholamines on plasma potassium: the role of alpha- and beta-adrenoceptors. Fundam Clin Pharmacol 1993;7:143–53, doi:10.1111/j.1472-8206.1993.tb00228.x.Google Scholar
12. Haffner, CA, Kendall, MJ. Metabolic effects of beta 2-agonists. J Clin Pharm Ther 1992;17:155–64, doi:10.1111/j.1365-2710.1992.tb01285.x.Google Scholar
13. Ruff, RL. Insulin acts in hypokalemic periodic paralysis by reducing inward rectifier K+ current. Neurology 1999;53:1556–63, doi:10.1212/WNL.53.7.1556.CrossRefGoogle ScholarPubMed
14. Sung, CC, Cheng, CJ, Lo, YF, et al. Genotype and phenotype analysis of patients with sporadic periodic paralysis. Am J Med Sci 2012;343:281–5.Google Scholar
15. Barahona, MJ, Vinagre, I, Sojo, L, et al. Thyrotoxic periodic paralysis: a case report and literature review. Clin Med Res 2009;7:96–8, doi:10.3121/cmr.2009.816.Google Scholar
16. Lin, SH, Lin, YF. Propranolol rapidly reverses paralysis, hypokalemia, and hypophosphatemia in thyrotoxic periodic paralysis. Am J Kidney Dis 2001;37:620–3, doi:10.1053/ajkd.2001.22090.CrossRefGoogle ScholarPubMed
17. Ober, KP. Thyrotoxic periodic paralysis in the United States. Report of 7 cases and review of the literature. Medicine 1992;71:109–20, doi:10.1097/00005792-199205000-00001.CrossRefGoogle ScholarPubMed
18. Liu, Z, Braverman, LE, Malabanan, A. Thyrotoxic periodic paralysis in a Hispanic man after the administration of prednisone. Endocr Pract 2006;12:427–31, doi:10.4158/EP.12.4.427.CrossRefGoogle Scholar
19. Miyashita, Y, Monden, T, Yamamoto, K, et al. Ventricular fibrillation due to severe hypokalemia induced by steroid treatment in a patient with thyrotoxic periodic paralysis. Intern Med 2006;45:11–3, doi:10.2169/internalmedicine.45.1495.Google Scholar
20. Wongraoprasert, S, Buranasupkajorn, P, Sridama, V, et al. Thyrotoxic periodic paralysis induced by pulse methylprednisolone. Intern Med 2007;46:1431–3, doi:10.2169/internalmedicine.46.0044.Google Scholar
21. Tessier, JJ, Neu, SK, Horning, KK. Thyrotoxic periodic paralysis (TPP) in a 28-year-old Sudanese man started on prednisone. J Am Board Fam Med 2010;23:551–4, doi:10.3122/jabfm.2010.04.090220.Google Scholar
22. Chaudhuri, A, Behan, PO. Myasthenic crisis. QJM 2009;102:97–107, doi:10.1093/qjmed/hcn152.Google Scholar
23. McGillicuddy, DC, Walker, O, Shapiro, NI, et al. Guillain-Barre syndrome in the emergency department. Ann Emerg Med 2006;47:390–3, doi:10.1016/j.annemergmed.2005.05. 008.Google Scholar
24. Edlow, JA, McGillicuddy, DC. Tick paralysis. Infect Dis Clin North Am 2008;22:397–413, doi:10.1016/j.idc.2008.03.005.Google Scholar